Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

Netherlands Cancer Institute (NKI)

Status and phase

Unknown

Phase 2

Conditions

Gastro Esophageal Junction Cancer

Stomach Cancer

Treatments

Drug: Docetaxel

Drug: Oxaliplatin

Drug: Capecitabine

Drug: Atezolizumab

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT03448835

N17PND

Details and patient eligibility

About

In this explorative study, patients with resectabel cancer of the stomach or stomach-oesophagealjunction cancer will receive neoadjuvant treatment.

The treatment will be 1 cyle atzolizumab monotherapy, followed by 4 cycle of atezolizumab and capecitabine, oxaliplatin and docetaxel.

Full description

In this single-centre, open-label, monocenter study, the investigators will enroll 20 patients with resectable cancer of the stomach of GEJunction.

All patients will be treated with 1 cycle of atezolizumab monotherapy, followed by 4 cycles of combinationtherapy of atezolizumab, capecitabine, oxaliplatin and docetaxel, followed by surgery.

Enrollment

20 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

signed informed consent
patients age 18 and older
primary resectable, histologically confirmed gastric or GEJ adenocarcinoma

Exclusion criteria

no signs of distant metastases
no active or history of autoimmune disease or immune deficiency
no significant cardiovascular disease
no major surgical procedure within 4 weeks prior to initiation of study treatment
no current treatment with anti-viral therapy or HBV
no pregnancy or breastfeeding
no history of malignancy within 3 years prior to screening